Trial register facet
Trial records in type 2 diabetes mellitus — page 4
247 records bearing on type 2 diabetes mellitus.
Showing 0 records on this page
Records
247 documents · page 4 of 11
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SURPASS-5 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 475 | 2022 | High |
| SURPASS-5-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| SURPASS-5-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| SURPASS-5-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
| STEP-2 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,210 | 2021 | High |
| SURPASS-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 478 | 2021 | High |
| SURPASS-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,879 | 2021 | High |
| SURPASS-3 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 1,444 | 2021 | High |
| SURPASS-4 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 2,002 | 2021 | High |
| AMPLITUDE-O | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 4,076 | 2021 | Moderate |
| STEP-2-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2021 | Very low |
| SURPASS-1-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| SURPASS-2-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| SURPASS-3-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2021 | Very low |
| SURPASS-4-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| AMPLITUDE-O-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| STEP-2-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| SURPASS-1-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| SURPASS-2-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2021 | Very low |
| SURPASS-3-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| SURPASS-4-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| AMPLITUDE-O-BODY-COMPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| STEP-2-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2021 | Very low |
| SURPASS-2-ADHERENCEprogramme record | Tirzepatide | Phase 3 | Reported | Observational | — | 2021 | Very low |
page 4 of 11